Allrock Bio has dosed the first participants in a small clinical trial testing ROC-101 as an add-on treatment for pulmonary ...

Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...

In a phase 2 trial, treatment with sotatercept shows reduced pulmonary vascular resistance and heart outcomes in patients ...

Scientists have created a new "molecular map" uncovering how an important human receptor involved in blood clotting and ...

Merck received positive results from a Phase 2 trial evaluating a treatment for pulmonary hypertension. Merck on Tuesday said its drug, Winrevair, met the primary endpoint in a Phase 2 study in adults ...

Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the pulmonary arteries, which transport blood from the heart to the lungs. This can ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

Please provide your email address to receive an email when new articles are posted on . Advancements in treatment directed by risk stratification and the availability of novel targeted therapy provide ...